IDH2 and glioblastoma: The remaining 31.7% of TERT-wildtype cases of our cohort of IDH-wt astrocytomas cases may represent true IDH-wt astrocytomas without molecular glioblastoma features, molecular IDH-wt glioblastomas with alternative defining alterations (EGFR amplification or +7/-10) that were not comprehensively assessed, or a mixture of both categories.